MedTrace Logo

Long-term Effectiveness of a Recombinant Hepatitis E Vaccine

NCT05976594 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2900

Last updated 2023-08-15

No results posted yet for this study

Summary

This test-negative study is designed to evaluate the long-term effectiveness of hepatitis E vaccine (Hecolin®) and to explore the prevalence of rat hepatitis E in Dongtai City.

Conditions

  • Hepatitis E

Interventions

DIAGNOSTIC_TEST

serology and virology detection of hepatitis E virus

Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.

Sponsors & Collaborators

  • Dongtai Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Dongtai Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Dongtai People's Hospital

    collaborator UNKNOWN

  • Xiamen University

    lead OTHER

Principal Investigators

  • Zhang Jun, M.D. · National Institute of Diagnostics and Vaccine Development in infectious disease, Xiamen University

Eligibility

Min Age
32 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-12
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05976594 on ClinicalTrials.gov